Abstract
Background Rapid atrial fibrillation (AF) is considered to be a trigger for heart failure (HF) decompensation. Few data are available on AF (particularly with a rapid ventricular response) as a trigger for HF decompensation and its effect on clinical outcomes.
Methods We studied 11,446 patients with acute HF. Rapid AF at admission was defined as ventricular rate ≥110 beats per minute, present at the first ECG performed after hospital arrival. The primary endpoint was in-hospital mortality.
Results Rapid AF (defined as ventricular rate ≥ 110 beats per minute) at admission was present in 609 patients (5.3%). In-hospital mortality occurred in 83 (13.6%) and 951 (8.8%) patients with and without rapid AF, respectively. In a multivariable Cox regression model, the HR for in-hospital mortality was 1.50 (95% 1.16 to 1.93, P<0.0001). With further adjustment for heart rate, the effect of rapid AF on in-hospital mortality was no longer significant (HR 1.11; 95% CI 0.83–1.50, P=0.48).
From the original cohort, 419 participants with rapid AF in admission were matched on their propensity score to 419 patients with sinus tachycardia. In-hospital mortality occurred in 62 (14.8%) and 61 (14.6%) patients with and without rapid AF, respectively. Compared with the sinus tachycardia group, the HR for the in-hospital mortality in patients with rapid AF was 0.98 (95% CI 0.68 to 1.42; P=0.93).
Conclusion Rapid AF in ADHF patients is associated with increased mortality risk that is mediated predominantly by rapid ventricular rate. The magnitude of the AF effect is similar to that of sinus tachycardia, indicating that the underlying mechanism for the adverse outcome is not directly related to AF.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Rambam Hospital Institutional Review Board
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
